Shares of Bio-Rad Laboratories Inc. (NYSE:BIO) saw unusually-high trading volume on Friday . Approximately 307,662 shares changed hands during mid-day trading, an increase of 147% from the previous session’s volume of 124,554 shares.The stock last traded at $155.90 and had previously closed at $155.02.

BIO has been the subject of several recent analyst reports. Jefferies Group restated a “buy” rating on shares of Bio-Rad Laboratories in a report on Wednesday, June 8th. Zacks Investment Research downgraded Bio-Rad Laboratories from a “hold” rating to a “sell” rating in a report on Tuesday, May 10th.

The firm has a 50-day moving average of $143.92 and a 200-day moving average of $138.99. The stock has a market capitalization of $4.58 billion and a P/E ratio of 47.29.

Bio-Rad Laboratories (NYSE:BIO) last released its quarterly earnings data on Wednesday, August 3rd. The company reported $0.61 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.13 by $0.52. The company earned $516.80 million during the quarter, compared to the consensus estimate of $497.80 million. During the same quarter last year, the business posted $0.97 earnings per share. The firm’s quarterly revenue was up 2.1% compared to the same quarter last year. Equities analysts anticipate that Bio-Rad Laboratories Inc. will post $3.10 EPS for the current fiscal year.

A number of hedge funds and institutional investors recently made changes to their positions in the company. Comerica Bank increased its position in shares of Bio-Rad Laboratories by 0.3% in the fourth quarter. Comerica Bank now owns 15,009 shares of the company’s stock valued at $1,959,000 after buying an additional 38 shares during the last quarter. Bank of Montreal Can increased its position in shares of Bio-Rad Laboratories by 13.1% in the fourth quarter. Bank of Montreal Can now owns 10,021 shares of the company’s stock valued at $1,390,000 after buying an additional 1,163 shares during the last quarter. Principal Financial Group Inc. increased its position in shares of Bio-Rad Laboratories by 3.5% in the fourth quarter. Principal Financial Group Inc. now owns 66,434 shares of the company’s stock valued at $9,212,000 after buying an additional 2,238 shares during the last quarter. BlackRock Advisors LLC increased its position in shares of Bio-Rad Laboratories by 4.7% in the fourth quarter. BlackRock Advisors LLC now owns 114,344 shares of the company’s stock valued at $15,855,000 after buying an additional 5,085 shares during the last quarter. Finally, Morgan Stanley increased its position in shares of Bio-Rad Laboratories by 356.6% in the fourth quarter. Morgan Stanley now owns 71,554 shares of the company’s stock valued at $9,921,000 after buying an additional 55,884 shares during the last quarter.

Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of life science research and clinical diagnostics products. The Company manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.